RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling
Drug Resistance Updates · 2026-07 · 87 · 101417
DOI: 10.1016/j.drup.2026.101417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-07. Verfasst von Baichuan Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Oxaliplatin, Antineoplastic Agents, Drug Resistance, Neoplasm, Stomach Neoplasms. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Anhui Provincial Key Research and Development Plan, Shanghai Shenkang Hospital Development Center, Science and Technology Innovation Plan Of Shanghai Science and Technology Commission.
Abstract (Originalsprache)
AIMS Resistance to oxaliplatin treatment limits therapeutic benefit in gastric cancer (GC) and remains difficult to predict from bulk biomarkers. We aimed to identify oxaliplatin resistance-driving malignant tumor states at single-cell resolution and translate them into clinically tractable predictors. METHODS Differential expression in oxaliplatin-resistant versus sensitive GC organoids was used to derive a resistance signature, which was evaluated in bulk GC organoid cohorts alongside computational estimate on oxaliplatin sensitivity. Single-cell RNA sequencing (scRNA-seq) was used to localize resistance programs to malignant epithelial states. A multi-constraint integration framework (Clinical-Transcriptomic Integration for Validation - Consensus Resistance Program, CTIV-CRP) was developed to prioritize candidates based on tumor enrichment, pharmacologic association, and reproducible prognostic relevance. Radiation sensitive1(RAD1) was further validated using public protein data, an independent neoadjuvant cohort assessed by tumor regression, and patient-derived organoid and xenograft models. RESULTS Resistance-associated activity associated with a malignant epithelial state (C2). CTIV-CRP distilled a core program in which RAD1 emerged as a consistent surrogate, aligning with resistance signatures and oxaliplatin sensitivity estimates. Clinical and experimental validations supported the association between RAD1 and poor therapeutic response. CONCLUSIONS CTIV-CRP connects single-cell malignant states to clinically relevant resistance phenotypes and nominates RAD1 as a candidate resistance biomarker in GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Clinical Research Institute, Eastern Hepatobiliary Surgery Hospital and National Center for Liver Cancer, Naval Medical University, Shanghai, China.
- The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
- Department of Urology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
- Department of Gastrointestinal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
- Clinical Research Institute, Eastern Hepatobiliary Surgery Hospital and National Center for Liver Cancer, Naval Medical University, Shanghai, China; Department of Hepatobiliary and Pancreatic Surgery, Tenth People's Hos…
Förderung
- Anhui Provincial Key Research and Development Plan
- Shanghai Shenkang Hospital Development Center
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
- National Natural Science Foundation of China
Zitieren
APA
Zhou, B., Zhang, S., Shen, Z., Si, Y., Luo, T., Shen, H., Wei, W., Yang, Q., Duan, M., Wang, Z., Feng, S., & Xu, A. (2026). RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling. Drug Resistance Updates, 87, 101417. https://doi.org/10.1016/j.drup.2026.101417
Vancouver
Zhou B, Zhang S, Shen Z, Si Y, Luo T, Shen H, et al. RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling. Drug Resistance Updates. 2026;87:101417. doi:10.1016/j.drup.2026.101417
BibTeX
@article{Zhou2026,
author = {Zhou, Baichuan and Zhang, Shichao and Shen, Zhemin and Si, Yuheng and Luo, Tianhang and Shen, Hao and Wei, Wenxin and Yang, Qiwu and Duan, Meiwen and Wang, Zhixian and Feng, Shiyao and Xu, Aman},
title = {RAD1 promotes oxaliplatin resistance in gastric cancer by reinforcing NRF2-driven antioxidant defense and DDR checkpoint signaling},
journal = {Drug Resistance Updates},
year = {2026},
volume = {87},
pages = {101417},
doi = {10.1016/j.drup.2026.101417}
}
EUVIMED